Clinical trialNCT06191640RecruitingObservational

Sinus Disease in Young Children With Cystic Fibrosis

SponsorUniversity of California, Los AngelesEnrollment80Chronic Rhinosinusitis (Diagnosis)Cystic FibrosisCystic Fibrosis in ChildrenOlfactory DisorderOlfactory Impairment

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel M Beswick, MD
University of California, Los Angeles
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Colorado
Aurora, Colorado, United States
Recruiting
University of Iowa
Iowa City, Iowa, United States
Recruiting
University of Kansas Medical Center
Kansas City, Kansas, United States
Recruiting
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Recruiting
University of Vermont
Colchester, Vermont, United States
Recruiting
University of Virginia
Charlottesville, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ivacaftor or elexacaftor/tezacaftor/ivacaftor

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Apr 2023
Primary completion: 30 Jun 2029
Completion: 30 Jun 2029
Last update posted: 11 May 2026
Registered enrollment: 80
Registry id: NCT06191640

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.